肺动脉高压药物治疗进展被引量：2

Advances in drug treatment of pulmonary hypertension

下载PDF

导出

摘要肺动脉高压分为原发性和继发性肺动脉高压。肺动脉高压具有药物治疗效果和预后差的特点。血管内皮功能减退与肺动脉高压的发生发展具有极其密切的关系。前列环素类似物、内皮素受体拮抗药等是新开发的有效治疗肺动脉高压的药物。 Pulmonary hypertension is divided into primary pulmonary hypertension and secondary pulmonary, hypertension. Pulmonary hypertension has the characteristics of poor effects of drug treatment and poor prognosis. Vascular endothelial dysfunction has close relation ship with the development of pulmonary hypertension and prostacyelin analogue, endothelin receptor antagonists are new drug for the treatment.

作者黄震华

机构地区上海交通大学医学院附属第九人民医院心血管病研究室

出处《中国新药与临床杂志》 CAS CSCD 北大核心 2006年第1期66-69,共4页 Chinese Journal of New Drugs and Clinical Remedies

关键词一氧化氰内支缩血管驮类内支血管肺动咏高压前列环素 nitrie oxide endothelins endothelium, vascular pulmonary hypertension prostacyclin

分类号 R541.5 [医药卫生—心血管疾病] R972.4 [医药卫生—药品]

引文网络
相关文献

参考文献20

1WANSTALL JC, JEFFERY TK. Recognition and management of pulmonary hypertension[J]. Drugs, 1998, 56(6) :989-1007.
2HOEPER MM, OLSCHEWSKI H, GHOFRANI HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension[J]. J Am Coll Cardiol, 2000, 35( 1 ) : 176-182.
3TUDER RM, COOL CD, GERACI MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension[J]. Am J Respir Crit Care Med, 1999,159(6) : 1925-1932.
4GALIE N, MANES A, BRANZI A. Emerging medical therapies for pulmonary arterial hypertension [J]. Prog Cardiovasc Dis,2002, 45(3) :213-224.
5McLAUGHLIN VV, SHILLINGTON A, RICH S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy[J]. Circulation, 2002, 106( 12): 1477-1482.
6BARST R J, RUBIN LJ, LONG WA, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension[J]. N Engl J Med, 1996, 334(5) :296-302.
7BADESCH DB, TAPSON VF, MCGOON MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial[J]. Ann Intern Med, 2000, 132(6) :425-434.
8SIMONNEAU G, BARST RJ, GALIE N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind,randomized, placebo-controlled trial[J]. Am J Respir Crit Care Med, 2002, 165(6) :800-804.
9NAGAYA N, UEMATSU M, OKANO Y, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension[J]. J Am Coll Cardiol, 1999, 34(4) : 1188-1192.
10GALIE N, HUMBERT M, VACHIERY JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised double-blind placebo-controlled trial[J]. J Am Coll Cardiol, 2002, 39 (9):1496-1502.